Key result
Heparin use with quinidine is linked to higher unbound quinidine and a ~13 ms longer RV ERP.
Why the study?
Pharmacodynamic and pharmacokinetic aspects relevant to the clinical application of unbound quinidine levels were not fully understood.
Does heparin administration or acute myocardial infarction alter unbound quinidine levels and its pharmacodynamic effects?
Observational (n=31)
Does heparin administration or acute myocardial infarction alter unbound quinidine levels and its pharmacodynamic effects?
Unbound quinidine concentrations and pharmacokinetics are significantly altered by heparin administration and during acute myocardial infarction, highlighting the need for clinical context when interpreting these levels.
Answers are grounded in this paper and cite their sources.
May warrant caution with heparin-quinidine coadministration; leaves open clinical relevance for arrhythmia management.
Pharmacodynamic and pharmacokinetic aspects pertinent to the potential clinical application of unbound quinidine levels were studied. Following heparin administration during electrophysiologic testing in 10 patients receiving quinidine, there were significant increases in the mean (+/- SD) right ventricular effective refractory period (266 +/- 24 versus 279 +/- 23; p less than 0.025), free fatty acid concentration (515 +/- 213 versus 1071 +/- 359 mmol/L; p less than 0.001), and unbound quinidine concentration (0.3 +/- 0.1 to 0.6 +/- 0.1 microgram/ml; p less than 0.001) but no changes in heart rate, corrected QT interval, or total plasma quinidine concentration. Ten control patients showed no change in the right ventricular effective refractory period following heparin administration. These findings were consistent with a heparin-induced increase in unbound drug concentration and activity that was limited to the vascular compartment. Eleven patients studied on day 3 (+/- 1) and day 10 (+/- 3) during an acute myocardial infarction showed a significant decrease in unbound quinidine fraction (12 +/- 4% versus 9 +/- 4%; p less than 0.02) accompanied by a decrease, rather than the predicted increase, in half-life (7.1 +/- 2.7 versus 6.3 +/- 2.1 hours; p less than 0.02). Volumes of distribution remained stable while the mean quinidine clearance tended to increase. Half-life correlated with albumin changes (r = -0.71; p less than 0.02). Apparently, improvement in clinical status (assumed) and drug clearance (measured) negated the direct effects of the decrease in unbound quinidine fraction. Although unbound drug concentrations should correlate best with drug dynamic and kinetic information, full knowledge of the clinical context of such measurements is needed for appropriate interpretation.
No takes yet. Share an insight, caveat, or question.
Kessler et al. (1989) conducted an observational in Patients receiving quinidine or with acute myocardial infarction (n=31). Heparin administration vs. Pre-administration and control patients was evaluated on Right ventricular effective refractory period (p=<0.025). Heparin administration in patients receiving quinidine increased the right ventricular effective refractory period and unbound quinidine concentration.
Synapse has enriched 10 related papers. Consider them for comparative context: